New Trial to Find Biomarkers to Guide Treatment
Drs. Jennifer Knox and Elizabeth Jaffee lead the PASS-01 trial using biomarkers and other measures to choose individualized treatment.
The Pancreatic Standard of Care is No Longer So Standard
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.
Adding Focused Radiation to Standard Pancreatic Cancer Treatment
Researchers are using IORT--intraoperative radiation therapy--to treat pancreatic cancer that cannot be surgically removed.
Time and Hope
Rose farmer Michael Francis wanted more time with his family, so he joined a clinical trial to treat his stage III pancreatic cancer.
Testing a New Approach to Treating Advanced Pancreatic Cancer
Scientists are testing a new drug that is an antagonist of stress hormone receptors, in combination with nab-paclitaxel, for advanced pancreatic cancer.
Shedding More Light On Neoadjuvant Treatment
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
Slowing the Spread of Advanced Pancreatic Cancer
Researchers are testing a kinase inhibitor that is used to treat lung diseases, including a type of lung cancer, against pancreatic cancer.
Targeted Therapy to Inhibit Connective Tissue Growth in Pancreatic Cancer
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.